Papaverine (Benzylisoquinoline Alkaloid · Non-opioid Vasodilator · Erectile Dysfunction Tx)
| Compound | Papaverine |
| Chemical class | Alkaloid — Isoquinoline (Benzylisoquinoline; non-opioid opium alkaloid) |
| CAS | 58-74-2 |
| Primary source | Papaver somniferum (opium, approximately 1% of latex) |
| Key applications | Pharmaceutical smooth muscle relaxant; erectile dysfunction (intracavernosal); vasodilator; informational reference |
| Claim strength | High (as pharmaceutical vasodilator/ED treatment); Informational only |
| Typical form | Pharmaceutical injection (intracavernosal for erectile dysfunction); oral extended-release tablet; not a dietary supplement |
| Buy from Herbuno | Browse HerbIQ Compound Index → |
Name origin: From Papaver (the genus). Papaverine was isolated from opium by Georg Merck in 1848. Unlike morphine, codeine, and thebaine (which have the morphinan scaffold), papaverine is a benzylisoquinoline — structurally distinct, with no morphinan ring system and no opioid receptor activity whatsoever. It is a pharmacologically non-addictive smooth muscle relaxant from the same plant that produces addictive opioids. Traditional use: Opium preparations containing papaverine (alongside morphine and codeine) have been used for antispasmodic and analgesic purposes since antiquity. The specific antispasmodic contribution of papaverine was not understood until its isolation and pharmacological characterisation in the 20th century. Pharmacology — PDE inhibition and calcium antagonism: Papaverine inhibits phosphodiesterase (PDE) enzymes non-selectively, increasing cAMP and cGMP and relaxing smooth muscle. It also blocks voltage-gated calcium channels. Unlike nitroglycerin and similar vasodilators, papaverine acts directly on smooth muscle without requiring endothelial function. Current pharmaceutical applications: (1) Intracavernosal injection for erectile dysfunction (alone or in Bi-Mix/Tri-Mix with phentolamine and/or alprostadil) — vasodilatory smooth muscle relaxation of the corpus cavernosum; (2) Vasospasm treatment (cerebral, coronary); (3) Ophthalmic surgery irrigation (smooth muscle relaxant). Supplement status: Pharmaceutical drug; not a dietary supplement.
Papaverine — Pharmacological Context
Erectile dysfunction — intracavernosal injection: Papaverine was the first pharmacological treatment for erectile dysfunction (injection therapy), introduced by Virag in 1982. Intracavernosal injection of papaverine 30–60 mg (alone or in combination) produces penile erection by relaxing the smooth muscle of the corpus cavernosum, allowing blood to fill the sinusoidal spaces. Replaced for most patients by PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis) which are oral and more convenient, but injection therapy with papaverine-containing mixtures remains the most effective option for patients who do not respond to PDE5 inhibitors. Pharmaceutical evidence: High.
PDE inhibition — non-selective and low potency: Papaverine inhibits all PDE isoforms non-selectively at relatively high concentrations. This non-selectivity is why papaverine cannot be used orally for erectile dysfunction at tolerated doses — systemic PDE inhibition causes hypotension, flushing, and tachycardia. The selective PDE5 inhibitors (sildenafil, tadalafil) achieve the same erectile effect at far lower concentrations with vascular selectivity, avoiding systemic side effects at therapeutic doses. Papaverine’s non-selectivity is pharmacologically informative — it helped identify the PDE pathway as the target for ED pharmacotherapy. Pharmacological reference.
Spinal cord injury and neurogenic ED: Papaverine injection remains particularly valuable for erectile dysfunction secondary to spinal cord injury or other neurogenic causes, where PDE5 inhibitor response is often absent (requires intact parasympathetic NO release from endothelium). The direct smooth muscle mechanism of papaverine bypasses the need for endothelial NO release, making it the treatment of choice for neurogenic ED. Pharmaceutical evidence: High (clinical specialty).
This compound is documented for research and formulator education purposes. For commercially available botanical ingredients, explore the HerbIQ Compound Index →
Frequently Asked Questions — Papaverine
Is papaverine addictive?
No — papaverine has no opioid receptor activity and no addiction potential. It is pharmacologically as different from morphine as aspirin, despite coming from the same plant. The benzylisoquinoline scaffold of papaverine does not interact with opioid receptors. This distinction is important: the opium poppy (Papaver somniferum) contains both addictive opioids (morphine, codeine, thebaine) and pharmacologically unrelated non-opioid alkaloids (papaverine, noscapine).
Why did sildenafil replace papaverine for most erectile dysfunction?
Oral sildenafil (Viagra, 1998) offered: (1) oral administration vs painful intracavernosal injection; (2) selective PDE5 inhibition vs non-selective PDE inhibition (better tolerability); (3) on-demand effectiveness (30–60 min before activity) vs injection timing flexibility. Papaverine injection is retained for: patients who cannot tolerate or do not respond to oral PDE5 inhibitors, neurogenic ED, and penile rehabilitation after prostatectomy. The intracavernosal injection route is not comfortable for most patients but produces reliable erections even in severely impaired vasculogenic ED.
What is Tri-Mix injection and what does papaverine contribute?
Tri-Mix is a compounded intracavernosal injection combining papaverine (smooth muscle relaxant via PDE inhibition), phentolamine (alpha-adrenergic blocker reducing sympathetic vasoconstriction), and alprostadil/PGE1 (prostaglandin E1, smooth muscle relaxation via adenylate cyclase). The three mechanisms are complementary — addressing different components of smooth muscle contraction in the corpus cavernosum. Tri-Mix allows lower doses of each component, reducing individual drug side effects while producing synergistic vasodilation.
Can papaverine be used for angina or cardiac vasospasm?
Papaverine has been used historically for coronary vasospasm (Prinzmetal angina) and cerebral vasospasm (post-subarachnoid haemorrhage). For coronary vasospasm, calcium channel blockers (diltiazem, verapamil) and nitrates have largely replaced papaverine due to better-characterised cardiac safety profiles. For post-SAH cerebral vasospasm, papaverine intra-arterial infusion is used in neurovascular intervention when other approaches fail, though evidence quality is limited. Nimodipine is the standard preventive treatment for cerebral vasospasm after SAH.
Related compounds: Morphine, Noscapine, Thebaine, Codeine
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery